New research suggests that rigorous blood pressure control is beneficial in early autosomal dominant polycystic kidney disease (ADPKD). Although a positive effect on the rate of decline of estimated glomerular filtration rate remains to be demonstrated, this study is likely to change current treatment strategies for young patients with ADPKD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kurschat, C. E. et al. An approach to cystic kidney diseases: the clinician's view. Nat. Rev. Nephrol. 10, 687–699 (2014).
Spithoven, E. M. et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol. Dial. Transplant. 29 (Suppl. 4), 15–25 (2014).
Schrier, R. W. et al. Predictors of autosomal dominant polycystic kidney disease progression. J. Am. Soc. Nephrol. 25, 2399–2418 (2014).
Schrier, R. W. et al. Blood Pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1402685.
Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1402686.
Chapman, A. B. et al. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5, 102–109 (2010).
Cornec-Le Gall, E. & Le Meur, Y. Polycystic kidney disease: Kidney volume—a crystal ball for ADPKD prognosis? Nat. Rev. Nephrol. 10, 485–486 (2014).
Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830–840 (2010).
Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820–829 (2010).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Acknowledgements
T.B. is supported by the German Research Foundation (BE2212 and SFB829, SFB832, SFB635). The author apologizes to those whose work could not be cited due to space limitations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.B. receives speaker honoraria from Hexal, Novartis and Otsuka.
Rights and permissions
About this article
Cite this article
Benzing, T. HALTing PKD progression—revival of blood pressure control. Nat Rev Nephrol 11, 129–131 (2015). https://doi.org/10.1038/nrneph.2014.241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.241
